Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers

BACKGROUND: HER2 mutation has been found to be an oncogenic driver gene in non-small cell lung cancers(NSCLC) and HER2-directed therapies have shown promising results in this unique population, while little is known about its association with outcomes of chemotherapy. The aim of this study was to in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yan, Zhang, Shijia, Wu, Fengying, Zhao, Jing, Li, Xuefei, Zhao, Chao, Ren, Shengxiang, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5869778/
https://www.ncbi.nlm.nih.gov/pubmed/29587667
http://dx.doi.org/10.1186/s12885-018-4277-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5869778/
https://www.ncbi.nlm.nih.gov/pubmed/29587667
http://dx.doi.org/10.1186/s12885-018-4277-x

Ejemplares similares